Background: Increasing use of genetic testing raises questions about disclosing secondary findings, including pleiotropic information.
Conclusion:
Disclosure of pleiotropic information did not increase anxiety or depression and may have decreased distress among persons at increased risk for 2 conditions. Providing risk modification information about CAD improved health behaviors. Findings highlight the potential benefits of disclosure of secondary genetic findings when options exist for decreasing risk. 
P
hysicians in all specialties are increasingly using genomic tools, including whole-genome and whole-exome sequencing (1-3) and genotyping for risk variants and pharmacogenomics variants (4, 5) . These tools often identify incidental or secondary findings that have important implications for disease but are unrelated to the original purposes of testing. Although recommendations exist for the reporting of secondary findings in genome sequencing (6, 7) , this topic remains controversial (8 -10) . In particular, experts are concerned that disclosing such information to patients may increase psychological risks while providing minimal clinical benefits (11) (12) (13) (14) (15) . Despite these concerns, few studies have empirically examined the benefits and harms of disclosure of secondary genomic findings.
Pleiotropy, the association between genetic variants and multiple disease traits, provides a useful model for examining this issue. An estimated 17% of genes have pleiotropic effects (16) . Pleiotropy poses challenges to communicating genetic test results because disclosing a genetic variant associated with a disease may unexpectedly confer knowledge of a separate disease risk (17) (18) (19) . The 4 allele of the apolipoprotein E (APOE) gene, which is present in more than 20% of most populations (20) , is robustly associated with risk for Alzheimer disease (AD) (21) and has a weaker and less well-known association with risk for coronary artery disease (CAD) (22, 23) . We previously conducted 2 randomized trials of APOE genotype disclosure during AD risk assessment, which showed that such disclosure did not increase psychological risks to volunteer populations (24, 25) and motivated at-risk participants to change potential AD risk-reducing behaviors (26, 27) . Neither trial addressed associations between APOE genotype and CAD.
In this article, we describe an independent trial in which we randomly assigned participants seeking a genetic risk assessment for AD to receive risk information on AD only (AD-only) or on AD and CAD (AD+CAD). We hypothesized that both groups would show equivalent levels of anxiety and depression 1 year after disclosure. We also conducted secondary analyses examining test-related distress and health behaviors.
METHODS

Design
The multidisciplinary REVEAL (Risk Evaluation and Education for Alzheimer's Disease) Study Group designed the study and risk disclosure procedures (24, 25, 28, 29) , including ethnicity-specific risk estimates (30, 31 ). An independent Ethics and Safety Board (ESB) and institutional review boards at each study site approved the protocol. Participants provided informed consent for initial steps during study enrollment and again before having blood drawn for genotyping. Genotyping of APOE was done at a Clinical Laboratory Improvement Amendments-certified facility. Figure 1 shows the design and flow of the study. After a telephone interview and completion of a written questionnaire, participants received brochures that summarized known benefits, risks, and limitations of APOE testing, including potential difficulties coping with test results and the lack of "proven ways to prevent Alzheimer's disease" (24, 29) (Supplement, available at www.annals.org). They then met with genetic counselors, who answered questions, and had blood drawn for genotyping. Approximately 1 month after the blood draw, participants received scripted information on genetic risk either in person or by telephone (depending on randomization) from 1 of 7 genetic counselors who also addressed any participant concerns. Participants were then followed for 1 year, with measurements at 6 weeks, 6 months, and 12 months.
Setting and Participants
We recruited cognitively healthy adults from Boston, Massachusetts; Cleveland, Ohio; Washington, DC; and Ann Arbor, Michigan, by using mailings to research registries, referrals from neurologists, and advertisements in local newspapers. To achieve greater sample diversity, we enrolled equal numbers of adults older and younger than 60 years and equal numbers of men and women. We also tried to enroll a sample in which 75% of participants had a single AD-affected firstdegree relative and 25% had no family history. We excluded persons with 2 or more AD-affected first-degree relatives or family members with average AD onset before age 60 years; those with scores less than 87 (after adjustment for education) on the Modified Mini-Mental State Examination (32) ; and those with severe anxiety and depression, as defined in the Outcomes and Follow-up section.
Randomization and Intervention
The primary goals of the trial focused on the effect of pleiotropic disclosure, but the opportunity to address a key question about service delivery led to the addition of a second randomization to compare telephone and in-person disclosure of genotyping results (these results will be reported in a separate manuscript). Participants were randomly assigned equally within strata, in blocks of 4, into "AD-only, in-person disclosure," "AD-only, telephone disclosure," "AD+CAD, in-person disclosure," and "AD+CAD, telephone disclosure" groups. Randomization strata were defined by site, age (<60 vs. ≥60 years), family history of AD, and sex. Randomization status was concealed in a serially numbered envelope until needed. Before randomization, participants were informed only that they would receive "different types of genetic risk information." Participants in the AD-only groups were not informed about associations between APOE genotype and CAD; those in the AD+CAD groups were told during a second consent step that they would receive information about CAD. Participants learned whether they would receive results in person or via telephone during their blood draw appointment.
During disclosure of genetic risk, all participants received scripted information about their APOE genotype, cumulative lifetime risk (range, 6% to 73%), and remaining risk for AD to age 85 years, along with AD risk curves (25, 30, 31) . Participants randomly assigned to the AD+CAD groups were also provided with the following statement orally and in writing, regardless of genotype: "In addition to Alzheimer's disease, APOE has been found to be connected to heart disease. Some studies have shown that people who carry e4 also have a higher risk of developing heart disease. Potential strategies to reduce the risk of coronary artery disease include smoking cessation, a healthy diet, weight loss, treatment of elevated cholesterol, and exercise (with your doctor's permission)." This information
EDITORS' NOTES Context
Genetic information may be used to inform persons about their risk for a specific disease. It is unknown whether providing information on risks for conditions about which the persons were not specifically seeking information is beneficial or harmful.
Contribution
This trial, in which participants were provided information on their risk for Alzheimer disease, found that also providing information on risk for coronary artery disease did not increase anxiety or depression but did improve health behaviors.
Implication
Disclosure of secondary findings of genetic tests may be safe in some conditions and may benefit some patients.
ORIGINAL RESEARCH
Disclosing Pleiotropic Effects During Risk Assessment for Alzheimer Disease was reiterated after each follow-up session. The statement was crafted to be appropriate for disclosure of secondary findings during AD risk assessment by a study cardiologist (D.L.B.) who conferred with cardiologists unrelated to the REVEAL Study.
Outcomes and Follow-up
Outcomes were assessed at 6 weeks, 6 months, and 12 months after disclosure, as summarized in Appendix Table 1 (available at www.annals.org). Primary outcomes were scores at 12 months on the Beck Anxiety Inventory (BAI) (33) and the Center for Epidemiologic Studies Depression Scale (CES-D) (34) , which are validated scales for measuring anxiety and depression. Scores on the BAI range from 0 to 63 (9 to 15 = mild, 16 to 25 = moderate, and >25 = severe), and CES-D scores range from 0 to 60 (11 to 16 = mild, 17 to 26 = moderate, and >26 = severe) (35) . Secondary outcomes included 6-week, 6-month, and time-averaged anxiety and depression scores, as well as test-related distress specific to the genetic risk assessment at all time points, which was measured with the Impact of Event Scale (IES) (36, 37) , with scores ranging from 0 to 75 (≥20 = significant distress). For safety purposes, an ESB-approved plan required immediate interview of participants whose BAI or CES-D scores exceeded 25 or 26, respectively, or increased by more than 15 points from baseline.
Secondary outcomes also included changes to health behaviors (diet, exercise, medications, dietary supplements, stress reduction, and mental activities) at 12 months. At 6 weeks, participants were asked, "Since you learned your APOE test results, have you made any health or wellness changes?" Participants who responded affirmatively answered additional questions about the types of behavior change they had initiated. At 12 months, participants were asked whether they had continued the changes reported at 6 weeks and were asked about additional changes initiated since the 6-week survey. Participants were coded as having made a health behavior change at 12 months if they continued a behavior reported at 6 weeks or if they initiated a behavior between the 6-week and 12-month surveys. Physical activity was assessed using the Rapid Assessment of Physical Activity (38), which scored participants on a scale of 1 to 7 for aerobic activity and 0 to 3 for strength and flexibility training. Smoking status was assessed at baseline and 12 months by asking participants whether they had smoked within the prior 7 days. To assess recall of pleiotropic information, each follow-up survey asked participants in the AD+CAD groups, "What other disease did we tell you is associated with the APOE gene?"
Statistical Analysis
We estimated that 32 participants in each group would need to receive genetic risk disclosure to achieve 80% power to detect 5-point differences between the AD+CAD and AD-only groups (39). We set enrollment targets of 70 participants at each study site to enroll 280 total participants and to achieve 256 total disclosures (assuming dropout of approximately 10%). 
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The sample size was expanded to allow for subanalyses by APOE genotypes and demographic factors. We used t tests and chi-square tests to compare demographic features and discontinuation rates in the AD-only and AD+CAD groups and participant variables associated with discontinuation. We initially designed the protocol using a superiority framework, but before seeing data and conducting analyses, we concluded that our scientific aims would be best served by the use of equivalence comparisons. Data for the telephone and in-person disclosure groups were pooled in analyses presented here because interactions between ADonly versus AD+CAD randomization status and inperson versus telephone disclosure randomization status were not observed (P values for tests of interactions were 0.18 for the BAI, 0.34 for the CES-D, and 0.68 for the IES; P values for tests of 3-way interactions between the treatment groups and time were all ≥0.40). Two participants who did not receive disclosure of genotype and AD risk and whose randomization status was mistakenly entered into the study database as AD-only were recoded as AD+CAD for analyses of study dropout.
We used longitudinal analyses for psychological outcomes, including all observed data and imputed data for the few missing observations from participants who received genetic risk disclosure. Because the distribution of these outcomes was skewed, we used generalized linear models fit with generalized estimating equations with a log link and a ␥ distribution to compare outcomes by AD-only versus AD+CAD randomization status. We used an autoregressive working correlation structure with robust SEs to account for repeated measures within participant. A value of 1 was added to all measures to shift the distribution away from zero. Models included terms for AD-only versus AD+CAD randomization status; time as a categorical variable; the interaction between time and randomization group; the corresponding baseline psychological measure, when applicable; and the genetic counselor providing disclosure. Additional analyses were further adjusted for age, sex, education, race, family history of AD, telephone or in-person disclosure, and APOE genotype. We used contrasts to compare randomization groups at specific time points and overall for a time-averaged comparison. Equivalence was defined using a margin of 5 points, per prior REVEAL Study trials (24, 25) . We used 95% CIs based on recommendations to use CIs of (1 Ϫ 2␣) × 100% for equivalence testing, with ␣ equal to 2.5% (0.05/2) to account for multiple testing across 2 primary outcomes (40, 41) . To be conservative and consistent across psychological outcomes, we also used 95% CIs for all secondary analyses. We evaluated whether interaction effects existed between AD-only versus AD+CAD randomization status and APOE genotype because pleiotropic information might concern participants only if they are at increased risk for both diseases. We used the model described earlier and added variables for the APOE 4 allele, its interaction with time, its interaction with pleiotropy randomization group, and the interaction among all three. From these analyses, we also obtained results for each APOE stratum for secondary analyses comparing pleiotropy groups. In addition, we used contrasts from these models to estimate the differences between carriers and noncarriers of the APOE 4 allele within randomization groups.
Secondary analyses tested for differences in rates of change in health behaviors and physical activity levels between the AD-only and AD+CAD groups and by APOE status. We compared rates of changes in health behaviors between groups by using logistic regression, allowing for the interaction with APOE genotype and adjusting for the genetic counselor providing disclosure. We compared changes in physical activity levels between groups by using multiple linear regression, with adjustment for APOE genotype and the genetic counselor providing disclosure. Changes to smoking status were assessed but are not reported because only 13 current smokers were enrolled.
Because APOE genotypes could not be reliably imputed, analyses included only participants receiving genetic risk information. Genotype data for participants who provided blood but dropped out of the study before the disclosure session were destroyed, per the protocol approved by the institutional review board. Two participants in the AD-only groups and 2 in the AD+CAD groups were excluded from the analysis for this reason. Twenty of the remaining 257 participants were missing BAI, CES-D, and IES scores. We assumed data were missing at random and imputed missing values for these outcomes by using multiple imputation 
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RESULTS
Of 290 participants randomly assigned, 257 (89%) received genetic risk disclosure (Figure 1) . Four participants were screened out (1 had a cognitive score below the eligibility criterion, 1 had a high depression score, 1 had an ambiguous family history of AD, and 1 did not attend study appointments). Other than race, demographic characteristics did not vary between the AD-only and AD+CAD groups ( Table 1 ) and were similar to those in our previous trials (24, 29) , except for the deliberate inclusion of participants without an affected first-degree relative. Genetic counselors communicated results to between 9 and 82 participants each and did not differ statistically in their likelihood of being randomly assigned to disclose AD-only or AD+CAD information (P = 0.58). Dropout before disclosure occurred in 8% of AD-only participants and 15% of AD+CAD participants (P = 0.061). Participants were more likely to drop out if they were younger (P = 0.003), female (P = 0.009), unmarried (P = 0.028), and less educated (P < 0.001), independent of randomization status (Appendix Table 2 , available at www.annals .org). At all time points, a high proportion of AD+CAD participants (81.3% at 6 weeks, 86.4% at 6 months, and 84.4% at 12 months) recalled receiving risk information about the association between APOE genotype and CAD.
Anxiety, Depression, and Test-Related Distress
Mean anxiety, depression, and test-related distress scores were below cutoffs for mood disorders regardless of disclosure protocol, at all time points, and when time-averaged ( Table 2 ). All 95% confidence bounds for between-group differences were within a margin of ±5 points. Equivalence was also supported in adjusted analyses (Appendix Table 3 , available at www .annals.org). Interactions between randomization status and time were not observed (P ≥ 0.57 for BAI; P ≥ 0.07 for CES-D; P ≥ 0.26 for IES).
Results on psychological scales by APOE group are presented in Table 3 . Anxiety and depression scores remained well below cutoffs for concern regardless of APOE 4 status, and 95% confidence bounds for mean differences between the AD-only and AD+CAD groups for each APOE genotype were within a margin of ± 5 points at all time points. However, among carriers of the APOE 4 allele, mean IES scores were lower at 12 months in the AD+CAD groups than in the AD-only groups, whereas mean IES scores did not differ among noncarriers (mean difference, Ϫ4.8 [95% CI, Ϫ8.6 to Ϫ1.0] for carriers and 0.6 [CI, Ϫ1.1 to 2.2] for noncarriers; P = 0.031 for interaction). Differences by APOE status were also observed at 6 months, when anxiety was modestly lower after receipt of AD+CAD information among APOE 4 carriers and modestly higher among noncarriers (mean difference, Ϫ1.8 [CI, Ϫ3.2 to Ϫ0.4] for carriers and 1.1 [CI, 0.1 to 2.0] for noncarriers; P = 0.004 for interaction). Findings from analyses stratified by APOE status were supported in adjusted analyses (Appendix Table 4 , available at www.annals.org).
Overall, 24% of study participants reported moderate anxiety, depression, or test-related distress at one or more follow-up time points, with no differences between the AD-only and AD+CAD groups over time (P = 0.53). As in prior REVEAL Study trials (24, 25) , mean IES scores were greater among APOE 4 carriers than among noncarriers in the AD-only groups (12-month mean difference, 3.8 [CI, 0.7 to 6.9]), whereas differences in mean depression scores by 4 status within AD-only groups were not observed (12-month mean difference, 1.6 [CI, Ϫ0.9 to 4.0]). Anxiety scores were higher among APOE 4 carriers than among noncarriers in the AD-only groups (12-month mean difference, 1.9 [CI, 0.1 to 3.7]). No differences were noted by 4 status in the AD+CAD groups.
Health Behavior Responses
Among all participants, 57% reported changing at least 1 health behavior at 12 months in response to genetic risk disclosure. The proportions reporting specific health behavior changes are shown in Appendix Table 5 (available at www.annals.org). Participants in the AD+CAD groups were more likely than those in the AD-only groups to report changes to most queried health behaviors, and differences were independent of APOE genotype (Figure 2) . Among the 36 participants who reported a medication change, 9 (25%) made a change related to CAD (such as blood pressure or cholesterol medications or fiber supplements). Secondary analyses also showed that APOE 4 carriers were more likely than noncarriers to report changes in all health behavior outcomes (Appendix Table 5 ). Differences were not observed between the AD+CAD and AD-only groups on 12-month aerobic activity scores (mean difference, 0.34 [CI, Ϫ0.09 to 0.76]) or strength and flexibility scores (mean difference, Ϫ0.01 [CI, Ϫ0.35 to 0.33]). Of note, 33% of participants in the AD+CAD groups reported sharing results with a health professional compared with 22% of those in the AD-only groups (P = 0.063).
DISCUSSION
We report a randomized trial of disclosure of pleiotropic risk information during genetic risk assessment for AD. Responses on the primary outcomes of anxiety and depression were equivalent between participants receiving information on AD risk plus secondary information on CAD risk and those receiving information on AD risk only, with no differences in mean scores at any time point and CIs within conservative margins for clinical significance. However, participants at increased risk for disease (APOE 4 carriers) seemed to experience less test-related distress at 12 months if they also received CAD information. Most other studies on the subject have shown no effect of genetic risk disclosure on general measures of mood but occasional short-term increases in test-related distress among persons at increased risk for disease (42) . Our results build on those findings by suggesting that "positive pleiotropic disclosure" (the disclosure of unsolicited risk information about a modifiable condition, such as CAD) may reduce distress in patients receiving risk information about a less readily modifiable condition, such as AD. These findings prompt the interesting speculation that worry about medically nonactionable genetic risk results may be mitigated by simultaneous receipt of actionable genetic risk results. Our study did not address "negative pleiotropic disclosure," such as choosing to learn APOE genotype for CAD risk and incidentally discovering its implications for AD risk, which could have yielded different results.
Nearly every health behavior we assessed improved in response to the AD+CAD information, regardless of APOE status. The statement about strategies to reduce CAD risk, which was given to all participants in the AD+CAD groups, may explain differences in reported changes in health behavior. However, participants receiving AD+CAD information were more likely to report sharing results with a health pro- 
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fessional, who may have in turn encouraged health behavior changes. Pleiotropic disclosure may also have prompted persons who had been focused on AD to attend to CAD, a more modifiable and prevalent condition. Carriers of the APOE 4 allele in both randomization groups were more likely than noncarriers to report changes to all health behaviors despite receiving education that highlighted a lack of proven options to reduce AD risk. Learning about an increased risk for AD and addressing pleiotropic outcomes may motivate persons to be healthier in general rather than motivating them to take steps to reduce risk for a specific disease.
Our participants were generally well-educated persons who volunteered for genetic risk assessment for AD, were not representative of the general population, and were more likely to have known about associations between APOE genotype and CAD independent of our study. This study focused on disclosure of pleiotropic information during single-gene testing for AD, and the results may not be generalizable to other conditions or to methods that can explore broader sets of genetic variants and diseases, such as genomic sequencing.
Our study excluded one person with a low cognitive score and one with severe depression, raising the possibility that results could differ among more vulnerable populations. We also omitted 33 randomly assigned participants who dropped out of the study before being genotyped. Self-reported outcomes, particularly those measuring health behaviors, are subject to bias due to participants responding in ways they believe investigators want them to (43) . Some of our health behavior measures have not been validated and do not provide insight about whether changes were clinically meaningful, although our physical activity measure has demonstrated validity for older adults (38). Finally, clinical outcomes associated with health behavior measures (such as weight loss) were not assessed.
Our study examined only one strategy for communicating associations between APOE status and CAD. Because of questions about the strength of the relationship between APOE genotype and CAD at the time of our study, we deliberately omitted quantified risk estimates for CAD from our disclosure statement that may have made pleiotropic disclosure more impactful. Indeed, meta-analyses published during our study sug- 
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Estimates are from an analysis using logistic regression and accounting for APOE status, its interaction with pleiotropy randomization group, and the genetic counselor providing disclosure (except for stress reduction, for which genetic counselor was omitted because some combinations of randomization status, APOE status, and genetic counselor had no events). Adjusted percentages are conditional probabilities estimated from the logistic model with all covariates set to their mean values (lsmeans statement in SAS). P values for interactions correspond to the P values from the interaction terms for randomization group by APOE status. The unadjusted numbers of participants reporting changes were 86 for diet, 91 for exercise, 76 for mental activities, 71 for dietary supplements, 57 for stress reduction, and 37 for medications. AD = Alzheimer disease; APOE = apolipoprotein E; CAD = coronary artery disease. 
